Hodgkin's Disease
105
4
6
82
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
34 trials with published results (32%)
Research Maturity
82 completed trials (78% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.5%
10 terminated out of 105 trials
89.1%
+2.6% vs benchmark
4%
4 trials in Phase 3/4
41%
34 of 82 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 82 completed trials
Clinical Trials (105)
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
MSC and HSC Coinfusion in Mismatched Minitransplants
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease